tbuckley/cabot-search huggingface dataset:
Appropriate Patient Selection Before Allogenic Stem Cell Transplantation (allo-SCT) and Chronic GvHD After Allo-SCT Would Be Necessary for Better Outcome of Chemorefractory Non-Hodgkin's Lymphomas-A Single Institute Retrospective Study-.
Authors: Nobuaki Nakano, Yosifusa Takatsuka, Shogo Takeuchi, Masahito Tokunaga, Mayumi Tokunaga, Ayumu Kubota, Takahiro Itoyama, Atae Utsunomiya
Journal: Blood (2009)
Phase I study of combined treatment with the oral alkyl-lysophospholipid (ALP) Perifosine and radiation in patients with advanced solid tumors
Authors: M. Verheij, S. R. Vink, J. H. M. Schellens, J. H. Beijnen, H. Sindermann, J. Engel, R. Dubbelman, G. Moppi, M. J. X. Hillebrand, H. Bartelink
Journal: Journal of Clinical Oncology (2004)

3064 Background: ALPs represent a group of anti-cancer drugs that primarily target the plasma membrane affecting both apoptotic and survival signaling. ALPs exert anti-angiogenic effects, act as radiosensitizers and synergistically enhance radiation-induced apoptosis in vitro. Based on these properties, the oral ALP Perifosine was considered an attractive candidate to combine with clinical radiotherapy. We previously established that a daily dose of 200 mg Perifosine is safe on a 21 day, q day 28 schedule. The purpose of this phase I study was to determine the feasibility and tolerability of concurrent daily Perifosine and radiation in patients with advanced cancer. Methods: The starting dose of Perifosine was 50 mg/day; dose escalation was in steps of 50 mg. Once daily administration commenced 2 days before radiotherapy and was continued throughout the radiation treatment. At least 3 patients were entered at each dose level; at the 150 mg/day level 10 patients were included. Blood samples were taken weekly pre-dosing and analyzed by LC/MS/MS, for pharmacokinetic analysis. Results: 21 patients were entered (17 males, 4 females), all WHO PS 0–1. Median age was 59 years (range 43–82). Tumor types included NSCLC (17), prostate (1), esophageal (1), colon (1) and bladder cancer (1). Most patients (14/21) had received prior chemotherapy; none radiotherapy. Median number of daily Perifosine administrations was 31 (range 24–53). Mean radiation dose (BED10) was 59.8 Gy (range 50.7 to 87.5 Gy in 13–28 fractions). Major toxicities according to CTC/RTOG criteria were anorexia grade 1–2 (n=4), nausea grade 1–2 (n=10), grade 3 (n=2), vomiting grade 1–2 (n=5), grade 3 (n=2), dysphagia grade 1–2 (n=4), grade 3 (n=1), diarrhea grade 1–2 (n=7), fatigue grade 1–2 (n=10). No bone marrow toxicity was observed. DLT (nausea/vomiting) was observed in 2 of 5 patients at the 200 mg/day dose level. Dose-dependent steady-state plasma levels were reached after 1 week. Conclusions: A dosage of 150 mg/day, to be started at least 1 week prior to radiotherapy, is recommended for phase II evaluation -in NSCLC and bladder cancer, based on responses seen. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Zentaris GmbH Zentaris GmbH Zentaris GmbH
P1.01-010 Awareness of Lung Cancer Risk Factors among Lay Persons and Physicians
Authors: Laurent Greillier, Jean-François Morere, Jérôme Viguier, Chantal Touboul, Jean-Yves Blay, François Eisinger, Christine Lhomel, Xavier Pivot, Alexis Cortot, Sébastien Couraud
Journal: Journal of Thoracic Oncology (2017)
The Impact of Donor Type In Patients with AML and High Risk Cytogenetic Aberrations
Authors: Johannes Schetelig, Dietrich Beelen, Michael Stadler, Herrad Baurmann, Gesine Bug, Frauke Bellos, Nicole Birninger, Stefanie Buchholz, Rainer Schwerdtfeger, Hans Martin, Ute Hegenbart, Martin Bornhäuser, Gerhard Ehninger
Journal: Blood (2010)
P1.01-012 Kava Effects on the Metabolism of Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) in Humans
Authors: Drew Oostra, Naomi Fujioka, Chengguo Xing, Sreekanth Narayanapillai, Jordan Paladino, Hannah Alves
Journal: Journal of Thoracic Oncology (2017)
Can we have some platelets please? A reason not to put your microscope on eBay
Authors: Wenchee Siow, Barbara J. Bain
Journal: American Journal of Hematology (2017)

A 63-year-old man presented to an Accident and Emergency department (located in an affluent part of central London) on a Saturday morning with abdominal pain, fever, diarrhea, and vomiting following a buffet meal. He had a background of type II diabetes mellitus. Platelets were noted to be 21 × 109/L on admission, hemoglobin concentration was 148 g/L and the white cell count was 5.1 × 109/L. Renal function was normal. He was treated for gastroenteritis, but his clinical condition deteriorated rapidly and he was noted to be more confused with a Glasgow Coma Scale of 11/15. He was also hypotensive and tachycardic. The clinical team contacted the hematology team on the Monday morning for approval of a platelet transfusion to cover a femoral line insertion. A blood film had previously been made but not looked at. The blood film, now examined, showed reactive lymphocytes and heavy parasitemia with Plasmodium falciparum (images). He was transferred to the intensive care unit and started on artemether and lumefantrine with good clinical effect. He continued to improve, was extubated two days later, and was discharged from hospital four days later with a platelet count of 366 × 109/L. Nothing to report.
Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: An on Going Joint Study of the AAWP EBMT Group and the French Society of Hematology
Authors: Régis Peffault de Latour, Hubert Schrezenmeier, Jean Yves Mary, Andrea Bacigalupo, Carmino De Souza, Roelof Willemze, Andre Tichelli, Jakob R. Passweg, Gerard Socié
Journal: Blood (2008)
Clinically Significant Mutations, Deletions and Translocations Involving ETV6 Identified by Whole Genome and Whole Exome Sequencing; Report From NCI/COG Target AML Initiative
Authors: Heather L. Helton, Rhonda E. Ries, Todd A. Alonzo, Robert B. Gerbing, Lisa R. Trevino, Jason Farrar, Jaime M. Guidry Auvil, Tanja M. Davidsen, Patee Gesuwan, Donna M. Muzny, Alan S. Gamis, Janet Franklin, David A. Wheeler, Malcolm A. Smith, Daniela S. Gerhard, Robert J. Arceci, Soheil Meshinchi
Journal: Blood (2012)
P264 Predicting mortality in hospital acquired pneumonia: a multivariate analysis
Authors: CB Morris, S Valapraya, E McCance, AM Turner, D Dosanjh
Journal: Thorax (2016)

<h3>Background</h3> Hospital Acquired Pneumonia (HAP) is defined as lung infection in a non-intubated patient with new infiltrates on chest X-ray, &gt;48 hours after hospital admission. Prediction scores exist for Community Acquired Pneumonia (CAP); no such scores exist in HAP. We aimed to identify features which are predictive of mortality in HAP. <h3>Methods</h3> All cases coded as HAP in Heart of England Foundation NHS trust in 2013 trust were identified (<b>293</b> cases). For each of these cases the chest X-ray (including radiologists report) was reviewed; if X-ray did not show infiltrates consistent with pneumonia, cases were excluded leaving <b>153</b> cases for whom case notes were reviewed. Cases were excluded if diagnosis of HAP was made &lt;48 hours after admission leaving <b>136</b> cases. Data was collected regarding demographics, co-morbidities, investigations, observations, mortality during admission and within 12 months. Univariate analysis was conducted to identify features associated with mortality. Multivariate analysis was completed using identified associated features. <h3>Results</h3> Sixty-four cases (47.0%) died during admission; and a further 32 within 12 months (70.5%). Demographics: Mean age was 81.6 years (range 52–98); mean number of co-morbidities was 5 (range 0–11). Mean haemoglobin was 110.9 g/dL. The mean white cell count (WCC) was 13.68 × 109/L (range 1.87–51.7 × 109/L). Mean urea was 10.5 mmol/L (range 1.9–6.1 mmol/L) Univariate analysis: Table 1 shows the results of the univariate analysis. Multivariate analysis: Only combination of raised urea and raised or low WCC were significantly associated with mortality (p = 0.024). Adding features of age, observations and co-morbidities did not improve prediction of mortality. <h3>Conclusion</h3> Prediction of mortality in HAP is more complex than in CAP. On multivariate analysis, raised urea and raised or low WCC were predictive of mortality. Other features including age, number of comorbidities and observations at the time of diagnosis were not associated with mortality. This perhaps reflects our elderly cohort, with the majority having multiple co-morbidities, with very small numbers aged &lt;65 years or with few co-morbidities. Further work with a larger dataset is ongoing.
Establishment of Cell Lines Stably Expressing HNA-1A, -1B, -2A, -4A, -4B, -5A and -5B Antigen with Low Background Reactivity in Flow Cytometric Analysis.
Authors: Kazuta Yasui, Toru Miyazaki, Yoshihisa Watanabe, Miki Odagiri, Nobuki Matsuyama, Rika A. Furuta, Takafumi Kimura, Hisami Ikeda, Fumiya Hirayama, Yoshihiko Tani, Hirotoshi Shibata
Journal: Blood (2007)
P3.01-036 Eukaryotic Translation Initiation Factors Impact Non-Small Cell Lung Cancer
Authors: Nadine Gantenbein, Eva Bernhart, Ines Anders, Joerg Lindenmann, Nicole Fink-Neuböck, Luka Brcic, Franz Gollowitsch, Elvira Stacher-Priehse, Jana Rolff, Jens Hoffmann, Christoph Reinhard, Helmut Popper, Wolfgang Sattler, Johannes Haybaeck
Journal: Journal of Thoracic Oncology (2017)
Prevalence, Incidence, and Mortality of Stroke in China
Authors: Wenzhi Wang, Bin Jiang, Haixin Sun, Xiaojuan Ru, Dongling Sun, Linhong Wang, Limin Wang, Yong Jiang, Yichong Li, Yilong Wang, Zhenghong Chen, Shengping Wu, Yazhuo Zhang, David Wang, Yongjun Wang, Valery L. Feigin
Journal: Circulation (2017)

Background: China bears the biggest stroke burden in the world. However, little is known about the current prevalence, incidence, and mortality of stroke at the national level, and the trend in the past 30 years. Methods: In 2013, a nationally representative door-to-door survey was conducted in 155 urban and rural centers in 31 provinces in China, totaling 480 687 adults aged ≥20 years. All stroke survivors were considered as prevalent stroke cases at the prevalent time (August 31, 2013). First-ever strokes that occurred during 1 year preceding the survey point-prevalent time were considered as incident cases. According to computed tomography/MRI/autopsy findings, strokes were categorized into ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and stroke of undetermined type. Results: Of 480 687 participants, 7672 were diagnosed with a prevalent stroke (1596.0/100 000 people) and 1643 with incident strokes (345.1/100 000 person-years). The age-standardized prevalence, incidence, and mortality rates were 1114.8/100 000 people, 246.8 and 114.8/100 000 person-years, respectively. Pathological type of stroke was documented by computed tomography/MRI brain scanning in 90% of prevalent and 83% of incident stroke cases. Among incident and prevalent strokes, ischemic stroke constituted 69.6% and 77.8%, intracerebral hemorrhage 23.8% and 15.8%, subarachnoid hemorrhage 4.4% and 4.4%, and undetermined type 2.1% and 2.0%, respectively. Age-specific stroke prevalence in men aged ≥40 years was significantly greater than the prevalence in women ( P &lt;0.001). The most prevalent risk factors among stroke survivors were hypertension (88%), smoking (48%), and alcohol use (44%). Stroke prevalence estimates in 2013 were statistically greater than those reported in China 3 decades ago, especially among rural residents ( P =0.017). The highest annual incidence and mortality of stroke was in Northeast (365 and 159/100 000 person-years), then Central areas (326 and 154/100 000 person-years), and the lowest incidence was in Southwest China (154/100 000 person-years), and the lowest mortality was in South China (65/100 000 person-years) ( P &lt;0.002). Conclusions: Stroke burden in China has increased over the past 30 years, and remains particularly high in rural areas. There is a north-to-south gradient in stroke in China, with the greatest stroke burden observed in the northern and central regions.
Variation in Performance of Neonatal Intensive Care Units in the United States
Authors: Jeffrey D. Horbar, Erika M. Edwards, Lucy T. Greenberg, Kate A. Morrow, Roger F. Soll, Madge E. Buus-Frank, Jeffrey S. Buzas
Journal: JAMA Pediatrics (2017)

Hospitals use rates from the best quartile or decile as benchmarks for quality improvement aims, but to what extent these aims are achievable is uncertain.To determine the proportion of neonatal intensive care units (NICUs) in 2014 that achieved rates for death and major morbidities as low as the shrunken adjusted rates from the best quartile and decile in 2005 and the time it took to achieve those rates.A total of 408 164 infants with a birth weight of 501 to 1500 g born from January 1, 2005, to December 31, 2014, and cared for at 756 Vermont Oxford Network member NICUs in the United States were evaluated. Logistic regression models with empirical Bayes factors were used to estimate standardized morbidity ratios for each NICU. Each ratio was multiplied by the overall network rate to calculate the 10th, 25th, 50th, 75th, and 90th percentiles of the shrunken adjusted rates for each year. The proportion in 2014 that achieved the 10th and 25th percentile rates from 2005 and the number of years it took for 75% of NICUs to achieve the 2005 rates from the best quartile were estimated.Death prior to hospital discharge, infection more than 3 days after birth, severe retinopathy of prematurity, severe intraventricular hemorrhage, necrotizing enterocolitis, and chronic lung disease among infants less than 33 weeks' gestational age at birth.Of the 756 hospitals, 695 provided data for 2014. The mean unadjusted infant-level rate of death before hospital discharge decreased from 14.0% in 2005 to 10.9% in 2014. In 2014, 689 of 695 NICUs (99.1%; 95% CI, 97.4%-100.0%) achieved the 2005 shrunken adjusted rates from the best quartile for death prior to discharge, 678 of 695 (97.6%; 95% CI, 95.8%-99.6%) for late-onset infection, 558 of 681 (81.9%; 95% CI, 77.2%-86.6%) for severe retinopathy of prematurity, 611 of 693 (88.2%; 95% CI, 81.7%-97.0%) for severe intraventricular hemorrhage, 529 of 696 (76.0%; 95% CI, 71.8%-81.2%) for necrotizing enterocolitis, and 286 of 693 (41.3%; 95% CI, 36.1%-45.6%) for chronic lung disease. It took 3 years before 445 NICUs (75.0%) achieved the 2005 shrunken adjusted rate from the best quartile for death prior to discharge, 5 years to achieve the rate from the best quartile for late-onset infection, 6 years to achieve the rate from the best quartile for severe retinopathy of prematurity and severe intraventricular hemorrhage, and 8 years to achieve the rate from the best quartile for necrotizing enterocolitis.From 2005 to 2014, rates of death prior to discharge and serious morbidities decreased among the NICUs in this study. Within 8 years, 75% of NICUs achieved rates of performance from the best quartile of the 2005 benchmark for all outcomes except chronic lung disease. These findings provide a novel way to quantify the magnitude and pace of improvement in neonatology.
Marinol-induced warm autoimmune hemolytic anemia.
Authors: A. Jajeh
Journal: Journal of Clinical Oncology (2011)

e13027 Background: Marinol is commonly used in the management of cachexia and poor appetite in patients with cancer. Marinol is a marijuana product that helps in stimulating appetite and controling nausea associated with chemotherapy. However, many adverse side effects reported with this drug ranging from euphorea to siezure and coma. This abstract is intended to shows that Marinol can induce sever warm autoimmune hemolytic anemia that required immediate discontiuation and steroid therapy with blood transfusion. Other medication and herbal suppliments prescribed to stimulate appetite and containing phytoesterol has been implicated in inducing immune hemolysis that can cause sever hemolysis and acute renal failue that end in hemodialysis. Methods: A 66 years old black male with stage IV metastatic colon cancer has been receiving FOLFOX with bevacizumab for nine cycles. Marinol was added to his therapy with cycle nine, no other new drug or herbal suppliment were added recently. Patient presented the next days with profound fatigue weakness and inability to eat or drink. Laboratory work up showed sever anemia with Hemoglobin of 6.5 g/dl, creatinin 16.9 and BUN 254, ferritin 6192, potassium 7.1, Na 134. LDH was 1753. WBC and platelets were elevated. Results: Review of peripheral smear shows many spherocytes with monocytes engolfing red cells, direct coombs test for poly and specific IgG was positive. Patient responded to steroids, immunoglobulins, blood transfusion and hemodialysis. Conclusions: Marinol can cause sever warm autoimmune hemolysis. Precautions should be exercised when using it in cancer patient. Marijuana and other phytoesterol containing food or herbal suppliment should be used with extreme precaution.
Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma
Authors: Kazunari Sasaki, Junichi Shindoh, Georgios A. Margonis, Yujiro Nishioka, Nikolaos Andreatos, Akinari Sekine, Masaji Hashimoto, Timothy M. Pawlik
Journal: JAMA Surgery (2017)

Background hepatocarcinogenesis is considered a major cause of postoperative recurrence of de novo hepatocellular carcinoma (HCC) in patients with liver cirrhosis (LC). The degree of underlying liver injury has reportedly correlated with surgical outcomes of HCC. However, the pattern and annual rate of recurrence of postoperative de novo HCC are still unclear.To clarify the pattern and rate of recurrence of de novo HCC in patients with LC.Data from 799 patients who underwent curative hepatectomy for HCC at Toranomon Hospital and The Johns Hopkins Hospital between January 1, 1995, and December 31, 2014, were retrospectively collected and analyzed. Of the patients who underwent curative hepatectomy for HCC, 424 met inclusion criteria: 73 with normal liver (NL) and 351 with LC. Sixty-four patients who had histologically proven NL parenchyma were matched with an equal number of patients who had established LC, and postoperative outcomes were compared.Hepatectomy in patients with HCC.Patterns of recurrence of HCC and chronological changes in recurrence rates.Among 128 matched patients in the study (mean [SD] age, 64.0 [12.7] years; 93 men and 35 women) 1-, 3-, and 5-year cumulative recurrence was 17.2%, 23.0%, and 37.5%, respectively, in the NL group vs 25.0%, 55.5%, and 72.1%, respectively, in the LC group (P = .001). The 3- and 5-year disease-specific survival was 85.7% and 75.4%, respectively, in the NL group vs 74.9% and 59.1%, respectively, in the LC group (P = .04). The median annual incidence of postoperative recurrence of HCC within 5 years after surgery was lower in the NL group (5.9%) compared with the LC group (12.7%) (P = .003). Assessment of recurrence patterns revealed that multiple recurrences near the resection margin or at extrahepatic sites were more frequent in the NL group (9 [50.0%] vs 6 [15.4%]; P = .01), whereas solitary recurrence at a distant site was more common in the LC group (21 [53.8%] vs 1 [5.6%]; P < .001).Comparison of the patterns and annual incidence of recurrence of HCC demonstrated that the poorer prognosis in the LC group was likely owing to a higher hepatocarcinogenic potential among patients with cirrhosis. Annual recurrence rates in the 2 groups indicate that de novo recurrence may continuously occur from the early postoperative period until the late period after resection of HCC.
Combination of Cladribine, Cytarabine and Topotecan (CLAT) for Relapsed or Refractory Acute Myeloid Leukemia
Authors: Xiaomei Chen, Jianyu Weng, Yulian Wang, Chengxin Deng, Chengwei Luo, Pengjun Liao, Minming Li, Xin Huang, Peilong Lai, Lisi Huang, Zhi Cao, Changchun Wan, Liye Zhong, Suijing Wu, Zesheng Lu, Xiaoli Zou, Xin Du
Journal: Blood (2015)
Spectrum of Diversity in Dermatology
Authors: Seemal R. Desai, Claudia Hernandez, Amy J. McMichael
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
P65 OSAS and driving – BTS return survey to assess consistency of advice given to patients at diagnosis and after treatment– a repeat of the 2013 survey to evaluate the impact of a BTS statement and new DVLA regulations
Authors: A Baluwala, D Ghosh, A Dwarakanath, M Twiddy, P Daxter, SL Jamson, M Elliott
Journal: Thorax (2016)

<h3>Introduction</h3> In 2013 a BTS survey showed substantial variability in the advice that patients with obstructive sleep apnoea syndrome (OSAS) would be likely to receive from clinicians with regard to whether they were fit to drive or not. Since then the BTS has issued guidance and the DVLA changed its emphasis to sleepiness “likely to impair safe driving”, rather than sleepiness in general. The survey was divided into two parts, the first focusing on patients at presentation and the second after treatment, with the wording of the questions reflecting that used in the DVLA forms. We repeated this study in 2016 to assess whether these changes had resulted in greater consistency. Additional questions about BTS and DVLA guidance were included. <h3>Methods</h3> Web based survey of members of BTS, BSS and ARTP. <h3>Results</h3> 304 respondents. The vignettes at diagnosis are directly comparable between the surveys and the results are very similar (p = NS). In the most contentious case there remains an approximately 50:50 chance of a patient receiving opposing advice. Significant variation in the assessments of control of patient’s condition, improvement in sleepiness and compliance after treatment remains (Figure 1). 2 36% were not aware that the BTS have issued a statement 63% felt the change in emphasis from excessive sleepiness to sleepiness likely to impair safe driving helpful. 64% of respondents were not aware that DVLA had changed its guidance in January 2016. 18% of respondents advise patients to inform the DVLA when diagnosis felt to be likely based on symptoms. 57% when diagnosis confirmed following investigation, 13% when CPAP first trialled and 12% when CPAP issued to the patient. <h3>Conclusions</h3> The results of the 2016 survey confirm the results of the 2013 survey. Disappointingly the guidance from the BTS appears to have had little impact. The change in emphasis from excessively sleepy to sleepiness likely to impair safe driving was felt to be helpful by a small majority. There is a clear need for tools which are felt to be robust by clinicians and patients to help make decisions about fitness to drive and for these to be disseminated to clinicians.
OA09.05 Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (FAZA) to Assess Tumor Hypoxia in Non-Small Cell Lung Cancer (NSCLC)
Authors: Angela Lin, Douglass Vines, Brandon Driscoll, Lisa Le, Stephen Breen, Alexander Sun
Journal: Journal of Thoracic Oncology (2017)